Ülke: Singapur
Dil: İngilizce
Kaynak: HSA (Health Sciences Authority)
MELOXICAM
BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.
M01AC06
7.5 mg
TABLET
MELOXICAM 7.5 mg
ORAL
Prescription Only
BOEHRINGER INGELHEIM PHARMA GMBH & CO KG
ACTIVE
1997-11-28
gji Abcd gji gji gji gji gji gji p gji gji Belgenin tamamını okuyun
MOBIC® abcd 1. NAME OF THE MEDICINAL PRODUCT MOBIC® Tablet 7.5mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 tablet contains 7.5 mg 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3- carboxamide-1,1-dioxide (= meloxicam) For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet 3.1 PRODUCT DESCRIPTION Round, pastel yellow, snap-tab tablets. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS MOBIC® is a non-steroidal anti-inflammatory drug indicated for - symptomatic treatment of painful osteoarthritis (arthrosis, degenerative joint disease). - symptomatic treatment of rheumatoid arthritis. - symptomatic treatment of ankylosing spondylitis. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY As the potential for adverse reactions increases with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The total daily dose of MOBIC® should be administered as a single dose. For adults the maximum recommended daily dose regardless of formulation is 15 mg. Painful osteoarthritis: 7.5 mg/day. If necessary, the dose may be increased to 15 mg/day. Rheumatoid arthritis: 15 mg/day. According to the therapeutic response, the dose may be reduced to 7.5 mg/day. Ankylosing spondylitis: 15 mg/day. SPECIAL POPULATIONS In patients with increased risks of adverse reactions, e.g. a history of gastro-intestinal disease or risk factors for cardiovascular disease, the treatment should be started at a dose of 7.5 mg/day (see Special warnings and precautions for use). No dose reduction is required in patients with mild or moderate renal impairment (i.e. in patients with a creatinine clearance of greater than 25 ml/min). In non-dialysed patients with severe renal impairment MOBIC® is contraindicated (see Contraindications). In patients with end-stage renal failure on haemodialysis the maximum daily dose should not exceed 7.5 mg/day. As a dosage for use in adolescents has not yet been established, usage should be restricted to adults. MET Belgenin tamamını okuyun